New hope for lung cancer: drug cocktail trial launches
NCT ID NCT06731907
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding a targeted drug called HER3-DXd to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced non-small cell lung cancer that hasn't been treated yet. About 90 participants will receive different combinations to see which works best and is safest. The goal is to improve tumor shrinkage and control the disease longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) plus chemotherapy and/or HER3-DXd (patritumab deruxtecan)
- What this could lead to
- If successful, this could lead to a more effective first-line treatment for advanced non-small cell lung cancer, potentially improving response rates and survival.
- What could go wrong
- This is an early phase 2 study with only 90 participants, so results may not apply to all patients. Adding new drugs also raises the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Abramson Cancer Center ( Site 0010)
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Ankara Bilkent Şehir Hastanesi ( Site 0142)
RECRUITINGAnkara, 06530, Turkey (Türkiye)
-
Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
ACTIVE_NOT_RECRUITINGAdana, 01250, Turkey (Türkiye)
-
Bradfordhill ( Site 0160)
RECRUITINGSantiago, Region M. de Santiago, 8420383, Chile
-
CNCE Precarpathian Clinical Oncologic Center ( Site 0131)
RECRUITINGIvano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine
-
CNE CC of Oncology Hematol ( Site 0130)
ACTIVE_NOT_RECRUITINGCherkasy, Cherkasy Oblast, 18009, Ukraine
-
Centro de Estudios Clínicos SAGA ( Site 0162)
RECRUITINGSantiago, Region M. de Santiago, 7500653, Chile
-
Chang Gung Medical Foundation-Linkou Branch ( Site 0182)
RECRUITINGTaoyuan, 33305, Taiwan
-
Changhua Christian Hospital ( Site 0181)
RECRUITINGChanghua, 50006, Taiwan
-
Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 0133)
RECRUITINGVinnytsia, Vinnytsia Oblast, 21029, Ukraine
-
European Interbalkan Medical Center-Oncology Department ( Site 0205)
RECRUITINGThessaloniki, 570 01, Greece
-
FALP ( Site 0161)
RECRUITINGSantiago, Region M. de Santiago, 7500921, Chile
-
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)
RECRUITINGMilan, Lombardy, 20133, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)
RECRUITINGRoma, 00168, Italy
-
HOSPITAL CLÍNIC DE BARCELONA ( Site 0092)
RECRUITINGBarcelona, 08008, Spain
-
Hacettepe Universite Hastaneleri ( Site 0140)
RECRUITINGAnkara, 06410, Turkey (Türkiye)
-
Hospital Universitario Quiron Madrid ( Site 0091)
RECRUITINGMadrid, 28223, Spain
-
IRCCS Ospedale San Raffaele ( Site 0171)
RECRUITINGMilan, 20132, Italy
-
Institut Català d'Oncologia - L'Hospitalet ( Site 0090)
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061)
RECRUITINGSzolnok, Jász-Nagykun-Szolnok, 5000, Hungary
-
MedStar Franklin Square Medical Center ( Site 0033)
RECRUITINGBaltimore, Maryland, 21237, United States
-
Meir Medical Center ( Site 0071)
RECRUITINGKfar Saba, 4428164, Israel
-
Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 0136)
RECRUITINGChernivtsi, Chernivetska Oblast, 58013, Ukraine
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
RECRUITINGWarsaw, Masovian Voivodeship, 02-781, Poland
-
Országos Korányi Pulmonológiai Intézet ( Site 0060)
RECRUITINGBudapest, 1121, Hungary
-
Petz Aladar Egyetemi Oktato Korhaz ( Site 0062)
RECRUITINGGyőr, Győr-Moson-Sopron, 9024, Hungary
-
Rabin Medical Center ( Site 0074)
RECRUITINGPetah Tikva, 4941492, Israel
-
Rambam Health Care Campus ( Site 0076)
RECRUITINGHaifa, 3109601, Israel
-
Sanford Cancer Center ( Site 0038)
RECRUITINGSioux Falls, South Dakota, 57104, United States
-
Sanford Fargo Medical Center ( Site 0039)
RECRUITINGFargo, North Dakota, 58102, United States
-
Shaare Zedek Medical Center ( Site 0075)
RECRUITINGJerusalem, 9103102, Israel
-
Shalimov Institute of Surgery and Transplantation ( Site 0135)
RECRUITINGKyiv, 03126, Ukraine
-
Sheba Medical Center ( Site 0070)
RECRUITINGRamat Gan, 5262000, Israel
-
Sourasky Medical Center ( Site 0077)
RECRUITINGTel Aviv, 6423906, Israel
-
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)
RECRUITINGKoszalin, West Pomeranian Voivodeship, 75-581, Poland
-
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 0204)
RECRUITINGAthens, Attica, 115 27, Greece
-
Taipei Medical University Hospital ( Site 0180)
RECRUITINGTaipei, 110, Taiwan
-
University of Kentucky ( Site 0019)
RECRUITINGLexington, Kentucky, 40536, United States
-
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
RECRUITINGGdansk, Pomeranian Voivodeship, 80-214, Poland
-
VISION PARTNER Medical Centre ( Site 0134)
ACTIVE_NOT_RECRUITINGKyiv, Kyivska Oblast, 03022, Ukraine
-
Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 0153)
ACTIVE_NOT_RECRUITINGPoznan, Greater Poland Voivodeship, 60-569, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?